StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research note issued to investors on Friday. The firm issued a sell rating on the medical technology company's stock.
Other analysts have also issued research reports about the stock. Benchmark cut their price objective on shares of BIOLASE to $7.00 in a research note on Wednesday, November 16th. Ascendiant Capital Markets cut their price objective on shares of BIOLASE to $14.00 in a research note on Wednesday, November 16th. Finally, Maxim Group dropped their price target on shares of BIOLASE from $10.00 to $5.00 in a research report on Friday, November 11th.Get BIOLASE alerts:
BIOLASE Stock Performance
BIOL opened at $1.02 on Friday. BIOLASE has a 52-week low of $0.93 and a 52-week high of $13.83. The company has a quick ratio of 1.27, a current ratio of 2.46 and a debt-to-equity ratio of 0.92. The company has a market cap of $7.25 million, a P/E ratio of -0.28 and a beta of 1.45. The firm's 50-day moving average price is $2.01 and its 200-day moving average price is $3.51.
Institutional Trading of BIOLASEInstitutional investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in shares of BIOLASE in the second quarter valued at about $118,000. Capital Wealth Alliance LLC acquired a new stake in shares of BIOLASE in the second quarter valued at about $51,000. Commonwealth Equity Services LLC grew its position in shares of BIOLASE by 117.8% in the first quarter. Commonwealth Equity Services LLC now owns 101,046 shares of the medical technology company's stock valued at $35,000 after purchasing an additional 54,650 shares during the period. Essex Investment Management Co. LLC grew its position in shares of BIOLASE by 62.3% in the third quarter. Essex Investment Management Co. LLC now owns 105,318 shares of the medical technology company's stock valued at $256,000 after purchasing an additional 40,440 shares during the period. Finally, Perkins Capital Management Inc. grew its position in shares of BIOLASE by 11.6% in the third quarter. Perkins Capital Management Inc. now owns 132,070 shares of the medical technology company's stock valued at $321,000 after purchasing an additional 13,770 shares during the period. Institutional investors and hedge funds own 21.21% of the company's stock.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.
- Get a free copy of the StockNews.com research report on BIOLASE (BIOL)
- Best Buy Proves Brick and Mortar is Here to Stay
- MarketBeat: Week in Review 11/21 – 11/25
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.